Market capitalization | $166.45m |
Enterprise Value | $184.70m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 2.58 |
P/S ratio (TTM) P/S ratio | 2.32 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | 41.35% |
Revenue (TTM) Revenue | $71.66m |
As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.
8 Analysts have issued a AVITA Therapeutics forecast:
8 Analysts have issued a AVITA Therapeutics forecast:
Mar '25 |
+/-
%
|
||
Revenue | 72 72 |
41%
41%
|
|
Gross Profit | 61 61 |
42%
42%
|
|
EBITDA | -50 -50 |
61%
61%
|
EBIT (Operating Income) EBIT | -51 -51 |
61%
61%
|
Net Profit | -57 -57 |
27%
27%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
AVITA Medical, Inc., through its subsidiaries, engages in the development and commercialization of a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs. Its product, RECELL system, is a device that enables healthcare professionals to produce a suspension of spray-on skin cells using a small sample of the patient's own skin for the treatment of acute thermal burns. The company was founded in December 1992 and is headquartered in Valencia, CA.
Head office | United States |
CEO | James Corbett |
Employees | 260 |
Founded | 1992 |
Website | www.avitamedical.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.